Compare · LUCD vs PAVM

LUCD vs PAVM

Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and PAVmed Inc. (PAVM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LUCD and PAVM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • LUCD is the larger of the two at $75.9M, about 8.3x PAVM ($9.1M).
  • Both names hit the wire about 7 times in the past 4 weeks.
  • LUCD has more recent analyst coverage (6 ratings vs 0 for PAVM).
MetricLUCDPAVM
Company
Lucid Diagnostics Inc.
PAVmed Inc.
Price
-
-
Market cap
$75.9M
$9.1M
1M return
-
-
1Y return
-
-
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2021
2016
News (4w)
7
7
Recent ratings
6
0
LUCD

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

PAVM

PAVmed Inc.

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Latest LUCD

Latest PAVM